Is ypTNM staging a comparable predictor as pTNM staging for survival in non-metastatic rectal cancer after preoperative chemoradiation therapy?

IF 2 4区 医学 Q3 ONCOLOGY Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI:10.32604/or.2024.052098
Jen-Pin Chuang, Hsiang-Lin Tsai, Wei-Chih Su, Po-Jung Chen, Ching-Wen Huang, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Yung-Sung Yeh, Tzu-Chieh Yin, Jaw-Yuan Wang
{"title":"Is ypTNM staging a comparable predictor as pTNM staging for survival in non-metastatic rectal cancer after preoperative chemoradiation therapy?","authors":"Jen-Pin Chuang, Hsiang-Lin Tsai, Wei-Chih Su, Po-Jung Chen, Ching-Wen Huang, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Yung-Sung Yeh, Tzu-Chieh Yin, Jaw-Yuan Wang","doi":"10.32604/or.2024.052098","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> The pTNM staging system is widely recognized as the most effective prognostic indicator for cancer. The latest update of this staging system introduced a new pathological staging system (ypTNM) for patients receiving neoadjuvant chemoradiotherapy (NACRT). However, whether the prognostic value of the ypTNM staging system for rectal cancer is similar to that of the pTNM staging system remains unclear. This study was conducted to compare the ypTNM and pTNM staging systems in terms of their prognostic value for patients with nonmetastatic rectal cancer undergoing proctectomy. <b>Material and Methods:</b> This study was conducted at a large teaching hospital. Between January 2014 and December 2022, 542 patients with rectal cancer were analyzed (median follow-up period, 60 months; range, 6-105 months). Of them, 258 and 284 were included in the pTNM and ypTNM groups, respectively. Inverse probability of treatment weighting (IPTW) was performed to account for the effects of confounders. Cox proportional-hazards regression was performed for the between-group comparison of overall survival (OS). <b>Results:</b> The crude model revealed that OS was similar between the two groups (<i>p</i> = 0.607). After performing IPTW, we found that patients with the same ypTNM- and pTNM-classified stages had similar overall survival (hazard ratio = 1.15; 95% CI = 0.76-1.73; <i>p</i> = 0.5074). <b>Conclusions:</b> For patients with rectal cancer who have received preoperative NACRT, the prognostic value of ypTNM staging appears to be similar to that of pTNM staging, mostly because of the downstaging effect of neoadjuvant chemoradiotherapy.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 11","pages":"1723-1732"},"PeriodicalIF":2.0000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497187/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2024.052098","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The pTNM staging system is widely recognized as the most effective prognostic indicator for cancer. The latest update of this staging system introduced a new pathological staging system (ypTNM) for patients receiving neoadjuvant chemoradiotherapy (NACRT). However, whether the prognostic value of the ypTNM staging system for rectal cancer is similar to that of the pTNM staging system remains unclear. This study was conducted to compare the ypTNM and pTNM staging systems in terms of their prognostic value for patients with nonmetastatic rectal cancer undergoing proctectomy. Material and Methods: This study was conducted at a large teaching hospital. Between January 2014 and December 2022, 542 patients with rectal cancer were analyzed (median follow-up period, 60 months; range, 6-105 months). Of them, 258 and 284 were included in the pTNM and ypTNM groups, respectively. Inverse probability of treatment weighting (IPTW) was performed to account for the effects of confounders. Cox proportional-hazards regression was performed for the between-group comparison of overall survival (OS). Results: The crude model revealed that OS was similar between the two groups (p = 0.607). After performing IPTW, we found that patients with the same ypTNM- and pTNM-classified stages had similar overall survival (hazard ratio = 1.15; 95% CI = 0.76-1.73; p = 0.5074). Conclusions: For patients with rectal cancer who have received preoperative NACRT, the prognostic value of ypTNM staging appears to be similar to that of pTNM staging, mostly because of the downstaging effect of neoadjuvant chemoradiotherapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ypTNM分期与pTNM分期相比,是否可预测术前化疗后非转移性直肠癌患者的生存率?
背景:pTNM分期系统是公认的最有效的癌症预后指标。该分期系统的最新更新引入了新的病理分期系统(ypTNM),适用于接受新辅助化放疗(NACRT)的患者。然而,ypTNM 分期系统对直肠癌的预后价值是否与 pTNM 分期系统相似仍不清楚。本研究旨在比较 ypTNM 和 pTNM 分期系统对接受直肠切除术的非转移性直肠癌患者的预后价值。材料与方法:本研究在一家大型教学医院进行。分析了 2014 年 1 月至 2022 年 12 月期间的 542 例直肠癌患者(中位随访期为 60 个月;范围为 6-105 个月)。其中,258 例和 284 例分别被纳入 pTNM 组和 ypTNM 组。为考虑混杂因素的影响,进行了治疗反概率加权(IPTW)。组间总生存期(OS)比较采用了 Cox 比例危险回归法。结果显示粗略模型显示,两组的 OS 相似(p = 0.607)。进行IPTW后,我们发现ypTNM分期和pTNM分期相同的患者总生存期相似(危险比=1.15;95% CI = 0.76-1.73;p = 0.5074)。结论对于术前接受了NACRT的直肠癌患者,ypTNM分期的预后价值似乎与pTNM分期相似,这主要是由于新辅助化放疗的降期效应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncology Research
Oncology Research 医学-肿瘤学
CiteScore
4.40
自引率
0.00%
发文量
56
审稿时长
3 months
期刊介绍: Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
期刊最新文献
Caffeic acid hinders the proliferation and migration through inhibition of IL-6 mediated JAK-STAT-3 signaling axis in human prostate cancer. CES1 is associated with cisplatin resistance and poor prognosis of head and neck squamous cell carcinoma. A comprehensive and systematic analysis of Dihydrolipoamide S-acetyltransferase (DLAT) as a novel prognostic biomarker in pan-cancer and glioma. Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development. hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: in-silico and in-vitro study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1